June 10th Event
“Why Long-Acting Injectables?"
"A Novel Transthyretin-Coupled Zwitterionic Depots for Long-Acting Injectables"
Dr. Mamoun Alhamadsheh
Mamoun M. Alhamadsheh, PhD, is Professor of Pharmaceutical Chemistry at the University of the Pacific and Scientific Co-Founder of Eidos Therapeutics. His research led to the discovery of acoramidis (formerly AG10) for transthyretin cardiac amyloidosis. His lab also focuses on extending drug half-life and improving targeting and delivery, resulting in the founding of MaHa Therapeutics. Dr. Alhamadsheh has numerous publications, multiple U.S. patents, and continuous NIH funding. He holds a PhD in medicinal chemistry from the University of Toledo, a bachelor's in pharmacy from Jordan University of Science and Technology, and completed postdoctoral training at Stanford University.
Developing Long-Acting Treatments Through Molecule Design and Formulation
Dr. William Rowe and Dr. David Stern - Gilead Sciences
William Rowe, PhD, is a Formulation and Process Development scientist at Gilead Sciences, Inc. He is experienced is bringing small molecules through Discovery, Development, and Commercialization.
His recent work has focused on development of long-acting therapies for the treatment and prevention of HIV.
William earned his PhD from the Massachusetts Institute of Technology.
David Stern, PhD, is a Formulation and Process Development Scientist at Gilead Sciences, Inc with expertise in small molecule formulation development from discovery to late-stage clinical development.
His recent work has focused on development of long-acting therapies for HIV treatment.
David earned his Bachelor’s degree in Chemical Engineering from the University of Florida and his PhD in Chemical and Biomolecular Engineering from The Johns Hopkins University.
Event Description:
- The event will begin at 5:00 PM with a 45-minute networking reception (including food and drinks) offering an ideal opportunity to meet peers and engage with professionals from a variety of backgrounds.
- Following the reception, our speakers will deliver two 45 minute (includig Q/A) talks that discuss various aspects of the importance of long acting injectables.
- The evening will conclude with ~45 minutes of additional networking, providing a relaxed space to continue conversations and build meaningful connections.
Wednesday, June 10th, 2026; 5:00 - 8:00pm PT
Genentech, 601 Gateway Blvd. 1st Floor, South San Francisco
$10 - regular fee
$5 – Student, Unemployed or Retired
